鹿児島大学病院は鹿児島県鹿児島市桜ケ丘八丁目にある大学病院。医学部と歯学部の附属病院である。2014年の患者数は、医科外来203,152名、歯科外来97,157名、医科入院204,339名、歯科入院10,103名である。

During the past decade, Kagoshima University Hospital conducted 48 clinical trials. In the 10-year time frame, 48 clinical trials started and 9 clinical trials were completed, i.e. on average, 18.8% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 9 clinical trials were completed. i.e. 27.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kagoshima University Hospital" #1 sponsor was "Pfizer" with 8 trials, followed by "Hoffmann-La Roche" with 7 trials sponsored, "Eli Lilly and Company" with 5 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored and "Actelion" with 4 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kagoshima University Hospital" #1 collaborator was "Astellas Pharma Inc" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator and "EPS Corporation" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Kagoshima University Hospital" are "Colitis, Ulcerative" (2 trials), "Crohn's Disease" (2 trials), "Juvenile Idiopathic Arthritis" (2 trials), "Macular Edema" (2 trials) and "Non-Small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Kagoshima University Hospital" in a lesser frequency.

Most popular intervention types in "Kagoshima University Hospital" are "Drug" (45 trials), "Other" (6 trials), "Biological" (5 trials), "Procedure" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Baricitinib" (3 trials), "Faricimab" (3 trials), "Sham Procedure" (3 trials) and "Aflibercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kagoshima University Hospital" are 46 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Kagoshima University Hospital". undefined are not yet recruiting, 13 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Kagoshima University Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Kagoshima University Hospital, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".